Phase II Study of Neoadjuvant Gemcitabine, Nab-paclitaxel, Durvalumab (MEDI4736) (Anti-PD-L1), and Oleclumab (Anti-CD73) in the Treatment of Resectable/Borderline Resectable Primary Pancreatic Adenocarcinoma
Summary
The purpose of this phase II trial is to evaluate the safety and efficacy of gemcitabine, nab-paclitaxel, durvalumab, and oleclumab in patients with resectable or borderline resectable pancreatic cancer.
General Information
NCT#: NCT04940286
Study ID: 2020-0898
Trial Phase: Phase II
Trial Sponsor: M.D. Anderson Cancer Center
Therapies Used in This Trial: Nab-paclitaxel, Gemcitabine, Durvalumab, Oleclumab